Form 8-K - Current report:
SEC Accession No. 0001213900-24-109891
Filing Date
2024-12-18
Accepted
2024-12-17 19:42:34
Documents
16
Period of Report
2024-12-13
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0225022-8k_inmed.htm   iXBRL 8-K 38990
2 STANDBY EQUITY PURCHASE AGREEMENT, DATED DECEMBER 13, 2024, BETWEEN INMED PHARMA ea022502201ex10-1_inmed.htm EX-10.1 289683
3 NEWS RELEASE, DATED DECEMBER 17, 2024 ea022502201ex99-1_inmed.htm EX-99.1 11597
7 GRAPHIC ex99-1_001.jpg GRAPHIC 5102
  Complete submission text file 0001213900-24-109891.txt   584486

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE inm-20241213.xsd EX-101.SCH 3021
5 XBRL LABEL FILE inm-20241213_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE inm-20241213_pre.xml EX-101.PRE 22364
19 EXTRACTED XBRL INSTANCE DOCUMENT ea0225022-8k_inmed_htm.xml XML 3673
Mailing Address 1445-885 WEST GEORGIA ST. VANCOUVER A1 V6C 3E8
Business Address 1445-885 WEST GEORGIA ST. VANCOUVER A1 V6C 3E8 (604) 669-7207
InMed Pharmaceuticals Inc. (Filer) CIK: 0001728328 (see all company filings)

EIN.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 001-39685 | Film No.: 241557331
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)